肺立体定向体部放疗后临床毒性反应与生活质量随辐射剂量和体积变化的分析
本研究纳入55例接受SBRT(12 Gy×4)的I期非小细胞肺癌患者,分析临床毒性与生活质量随剂量体积参数的变化。中位随访24个月,3年局部控制率93%、无病生存率65%、总生存率84%,3级毒性发生率5.5%,无4级或5级毒性。患者报告的生活质量临床显著下降与V10、V13、V20等剂量学参数增加显著相关。
要点
- 55例I期NSCLC患者接受SBRT(12 Gy×4),3年局部控制率93%、总生存率84%。
- 3级毒性发生率5.5%,无4级或5级毒性反应。
- 生活质量临床显著下降与V10、V13、V20增加显著相关。
核心结论
- 肺SBRT对早期NSCLC具有优良的局部控制和极少的临床毒性,但生活质量的临床显著下降与肺剂量和体积参数增加显著相关。
研究设计与样本
- 经机构审查委员会批准的研究,分析55例接受SBRT(12 Gy×4)并完成生活质量表格的I期NSCLC患者。
- 临床毒性和生活质量在基线和SBRT后3、6、12、18、24、36个月测量。
- 毒性采用不良事件通用术语标准4.0版分级,生活质量采用经验证的功能性癌症治疗-肺-试验结果指数(FACT-L-TOI)量表。
- 剂量学参数包括平均肺辐射剂量和正常肺接受大于5、10、13或20 Gy的体积(V5、V10、V13、V20)。
- 采用Student t检验和Pearson相关分析检验肺辐射指标与生活质量临床有意义变化和/或临床毒性之间的关系;Kaplan-Meier法估计局部控制、无病生存和总生存率。
主要发现
- 中位随访24个月,3年局部控制率93%、无病生存率65%、总生存率84%。
- 3级毒性发生率为5.5%,无4级或5级毒性反应。
- 患者报告的生活质量(FACT-L-TOI、肺癌子量表、身体健康和/或功能健康)临床显著下降与V10、V13、V20等剂量学参数增加显著相关。
关键数值与推荐
- SBRT方案为12 Gy×4。
- 3年局部控制率93%、无病生存率65%、总生存率84%。
- 3级毒性发生率5.5%,无4级或5级毒性。
- 生活质量临床显著下降与V10、V13、V20增加显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze clinical toxicity and quality-of-life (QOL) outcomes among patients with stage I non-small cell lung cancer (NSCLC) after stereotactic body radiation therapy (SBRT) as a function of radiation dose and volume parameters. METHODS AND MATERIALS: In this institutional review board-approved study, 55 patients with stage I NSCLC who received SBRT (12 Gy × 4) and completed QOL forms were analyzed. Clinical symptoms and QOL outcomes were measured at baseline and at 3, 6, 12, 18, 24, and 36 months after SBRT. Clinical toxicity was graded using the Common Terminology Criteria for Adverse Events, version 4.0. Quality of life was followed using the validated Functional Assessment of Cancer Therapy-Lung-Trial Outcome Index (FACT-L-TOI) instrument. Dosimetric parameters including the mean lung radiation dose and the volume of normal lung receiving greater than 5, 10, 13, or 20 Gy (V5, V10, V13, and V20) were measured from the radiation treatment plan. Student t tests and Pearson correlation analyses were used to examine the relationships between radiation lung metrics and clinically meaningful changes in QOL and/or clinical toxic effects. The Kaplan-Meier method was used to estimate rates of local control (LC), disease-free survival (DFS), and overall survival (OS). RESULTS: With a median follow-up of 24 months, the 3-year LC, DFS, and OS were 93%, 65%, and 84%, respectively, with a 5.5% rate of grade-3 toxic effects and no grade 4 or 5 toxic effects. Clinically meaningful declines in patient-reported QOL (FACT-L-TOI, lung cancer subscale, physical well-being, and/or functional well-being) posttreatment significantly correlated with increased dosimetric parameters such as V10, V13, and V20. CONCLUSION: Although lung SBRT was associated with excellent LC and minimal clinical toxic effects for early-stage NSCLC, clinically meaningful declines in QOL were significantly correlated with increasing lung dose and volume parameters.
引用
- Devpura S, Feldman AM, Rusu SD, et al. An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2021. PMID: 34934866. doi:10.1016/j.adro.2021.100815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。